07:00 , Mar 23, 2015 |  BioCentury  |  Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Charles River, Galapagos deal

Charles River completed its acquisition of the Argenta Discovery Ltd. and BioFocus DPI Ltd. drug discovery service divisions of Galapagos for €129 million ($177.5 million) in cash, plus up to €5 million ($6.9 million) in...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Charles River, Galapagos deal

Charles River will acquire the Argenta Discovery Ltd. and BioFocus DPI Ltd. drug discovery service divisions of Galapagos in a deal worth up to €134 million ($186.2 million). Galapagos will receive €129 million ($179.3 million)...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic...
23:39 , Mar 13, 2014 |  BC Extra  |  Company News

Charles River to acquire Galapagos service divisions

CRO Charles River Laboratories International Inc. (NYSE:CRL) will acquire the Argenta Discovery Ltd. and BioFocus drug discovery service divisions of Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) in a deal worth up to EUR 134 million ($186.2 million)....
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Galapagos, Boehringer Ingelheim deal

Galapagos' BioFocus service division will discover drugs against an undisclosed target from Boehringer. Galapagos declined to disclose details, and Boehringer could not be reached. Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium   Boehringer Ingelheim GmbH ,...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Biogen Idec, Galapagos deal

Biogen Idec partnered with Galapagos' BioFocus service division to identify and validate novel targets in scleroderma. Under the three-year deal, BioFocus will use its SilenceSelect gene knock-down technology and human skin models to deliver new...
08:00 , Nov 14, 2013 |  BC Innovations  |  Tools & Techniques

Scleroderma models: skin in the game

Systemic scleroderma involves fibrosis of the skin and internal organs, but its etiology is poorly understood and it has no known genetic causes-factors that have hampered the development of models and, in turn, therapies. Now,...
01:04 , Nov 13, 2013 |  BC Extra  |  Company News

Biogen Idec, Galapagos in scleroderma target discovery deal

Biogen Idec Inc. (NASDAQ:BIIB) partnered with the BioFocus service division of Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) to identify and validate novel targets in scleroderma. Under the three-year deal, BioFocus will use its SilenceSelect gene knock-down technology...